Baker McKenzie advised Swissroc Asset Management on the acquisition of an office building in downtown Geneva from an institutional seller. The building is approx. 1,200 square meters in size, ideally situated in a strategic location, a
Search Results for: baker mckenzie
Baker McKenzie advised GEHAG Real Estate on the sale of an attractive residential property consisting of three buildings in Wetzikon to UTILITA Anlagestiftung für gemeinnützige Immobilien. Baker McKenzie Switzerland advised GEHAG Real Estate
In a landmark move, Baker McKenzie provided strategic counsel to VT5 Acquisition Company, a SIX-listed Swiss SPAC, on its acquisition of R&S International Holding. The compelling business combination, backed by an impressive 99% shareholder
Baker McKenzie Switzerland played a pivotal role in advising Swiss Prime Site Immobilien on acquiring the prestigious office property “Fifty-One” at Pfingstweidstrasse 51 in Zurich-West. The LEED Gold-certified building spans approximately 21,000 m2 with 88 parking spaces, generating
Baker McKenzie Switzerland played a pivotal role in advising Mateco group on its acquisition of Maltech Holding and subsidiaries, the prominent Swiss market leader in rentable lifting platforms. This acquisition marks a significant stride in
Baker McKenzie Switzerland played a pivotal role in advising Lalique Group on the acquisition of a substantial 75% stake in the renowned wine estate, Château Lafaurie-Peyraguey, for a notable EUR 18 million. This strategic move not
Baker McKenzie advised Commerzbank Aktiengesellschaft and Credit Suisse (Switzerland) Ltd. in their capacities as joint mandated lead arrangers, coordinators and bookrunners in connection with a CHF 500-million senior multicurrency revolving credit facility agreement for Geberit,
Baker McKenzie, with its teams in Singapore, Switzerland, and Japan, served as legal advisor to DBS Bank, UBS, and SBI Digital Asset Holdings in executing the world’s first cross-border repo and natively-issued digital bond
Luzerner Kantonalbank acted as arranger, agent, security agent and lender, along with other Swiss and Liechtenstein banks as lender in connection with their EUR 150 million financing of GarLa AcquiCo and its subsidiaries, GarLa Group. The
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has acquired the 68.0% of the shares in Swiss pharmaceutical company Osmopharm and has disinvested the 76.4% in Egyptian pharmaceutical manufacturer SPIMACO Misr for Pharmaceutical Industries. The Transaction, with